NCT02092142

Safety and Immunogenicity of Q Fever Vaccine

Evaluation of the Safety and Immunogenicity of Q Fever Vaccine, Phase I, Inactivated, Dried, NDBR 105, in Subjects at Risk of Exposure to Coxiella Burnetii

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: U.S. Army Medical Research and Development Command · Federal
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the safety of Q Fever Vaccine, Phase I, Inactivated, Dried, NDBR 105 and collect data on incidence of occupational Q fever infection in vaccinated personnel.

Conditions

• Q Fever

Interventions

Type	Name	Description
BIOLOGICAL	Q fever Vaccine	Subcutaneous 0.5 mL Q fever Vaccine, Phase I, Inactivated, Dried, NDBR 105

Timeline

• Start date: 2006-02-01
• Primary completion: 2019-02-01
• Completion: 2019-12-01
• First posted: 2014-03-20
• Last updated: 2020-01-02

Locations

1 site across 1 country: United States